Atopic Dermatitis

Experts report that among skin diseases, atopic dermatitis has the lowest reported quality of life.

Patients who have extrinsic (EAD) or intrinsic atopic dermatitis (IAD) serve to benefit equally from dupilumab, even when considering immunoglobulin E levels, which are elevated in EAD but remain normal in IAD.

A recent survey assessed the factors that adult patients with eczema and caregivers find important regarding clinical trial participation decision-making.

Study investigators stress the importance of health care professionals familiarizing themselves with risk factors among a more diverse patient population.

The study findings suggest that treatments for allergic reactions could help decrease the risk of having joint problems.

By better understanding the nature of atopic dermatitis and its varying comorbidities, providers might be able to better predict patient outcomes, said Raj Chovatiya, MD, PhD, assistant professor of dermatology, Northwestern University Feinberg School of Medicine.

Key opinion leaders navigate diagnostic challenges associated with atopic dermatitis.

Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.

Lack of knowledge about how skin conditions present on lightly pigmented skin has resulted in diagnostic delays, underassessment, and an impact on quality of life for patients with skin of color.

Investigators compared outcomes for severe mental illness between patients with both chronic skin conditions and healthy controls, using data from the UK Clinical Practice Research Datalink GOLD.

While the future is bright with potential for personalized medicine to treat atopic dermatitis, current treatment is still more like trial and error, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.

This study investigated potential benefits of a virtual education intervention for atopic dermatitis that targeted Hispanic Americans and Spanish-speaking populations.

Mental health is an underrepresented issue in dermatology even though numerous skin diseases are associated with mental health diseases, said Eva R. Parker, MD, associate professor of dermatology at Vanderbilt University Medical Center and president of the Nashville Dermatologic Society.

Data from the LIBERTY AD PRESCHOOL trial, and its ongoing open-label extension analysis show that dupilumab is safe and clinically effective, and can lead to statistically significant symptom improvement among patients aged 6 months to 17 years who have moderate to severe atopic dermatitis (AD).

Investigators of this study noted the need for more data on risks of malignancies among patients who have atopic dermatitis (AD), with the chronic skin condition already having significant associations with nonmelanoma skin cancer, lymphoma, keratinocyte carcinoma, and pancreatic and kidney cancers.

A meta-analysis and review of 9 randomized trials found high-quality evidence demonstrating the benefits of dupilumab in patients with severe atopic dermatitis.

A group of dermatologists and dermatology students studied why atopic dermatitis may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity.

Study results presented at this year’s American Academy of Allergy Asthma & Immunology annual meeting displayed dupilumab efficacy in children aged 6 months to 5 years who had atopic dermatitis (AD).

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

This study investigated the impact atopic dermatitis (AD) has on out-of-pocket (OOP) costs for caregivers of pediatric patients with the chronic skin condition.

This exploration of eczema self-management investigated the potential effectiveness of 2 online behavioral interventions, 1 each for young patients and their parents and/or caregivers.

The authors conducted a subanalysis of data on 100,000-plus children from 3 studies to estimate the global prevalence and severity of eczema; they used linear mixed models to do so.

With atopic dermatitis (AD) prevalence increasing around the world, primarily in developing countries, investigators evaluated the potential for pollution to have an impact on development of the chronic skin condition among an adult population.

A team of experts from the United States and Canada performed this systematic review, considering for the first time patient values and preferences for their atopic dermatitis (AD) care.

Following member surveys, expert interviews, and roundtable discussions, the American College of Allergy, Asthma, and Immunology (ACAAI) has released new recommendations for overcoming care disparities among those who have atopic dermatitis (AD) and food allergies.

Using data from the UK Biobank, potential correlations were investigated between excessive skin scarring outcomes arising from comorbidities among 230,000-plus European individuals.

The parents of pediatric patients who have atopic dermatitis experience stress just as their children do, and this study investigated how that stress manifests among the parents, comparing outcomes between mothers and fathers.

For 2 important reasons—that brain cancer is so aggressive and its risk may be elevated in the presence of certain allergies—investigators of a meta-analysis set out to investigate potential connections between eczema and various brain cancers.

With mixed findings from previous studies focused on atopic dermatitis and the use of cognitive behavioral therapy (CBT) as a treatment modality, investigators modified an existing online CBT intervention to account for the lack of clinical psychologists in the dermatological space.

This year’s most-read articles on atopic dermatitis (AD) examined AD as a risk factor for other neurological and attention-deficit conditions and efforts to improve the detection of other comorbid conditions associated with the common skin condition.